- Home
- HSHP vs ABEO Comparison
HSHP vs ABEO Comparison
Compare HSHP & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- ABEO
- Stock Information
- Founded
- HSHP 2021
- ABEO 1974
- Country
- HSHP Bermuda
- ABEO United States
- Employees
- HSHP N/A
- ABEO N/A
- Industry
- HSHP
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- ABEO Health Care
- Exchange
- HSHP Nasdaq
- ABEO Nasdaq
- Market Cap
- HSHP 268.1M
- ABEO 256.9M
- IPO Year
- HSHP 2023
- ABEO 1980
- Fundamental
- Price
- HSHP $5.98
- ABEO $6.24
- Analyst Decision
- HSHP
- ABEO Strong Buy
- Analyst Count
- HSHP 0
- ABEO 5
- Target Price
- HSHP N/A
- ABEO $17.80
- AVG Volume (30 Days)
- HSHP 74.7K
- ABEO 1.7M
- Earning Date
- HSHP 06-10-2025
- ABEO 05-15-2025
- Dividend Yield
- HSHP 7.52%
- ABEO N/A
- EPS Growth
- HSHP 185.76
- ABEO N/A
- EPS
- HSHP 0.28
- ABEO N/A
- Revenue
- HSHP $121,972,000.00
- ABEO N/A
- Revenue This Year
- HSHP $11.22
- ABEO N/A
- Revenue Next Year
- HSHP $25.90
- ABEO $383.07
- P/E Ratio
- HSHP $22.77
- ABEO N/A
- Revenue Growth
- HSHP 107.17
- ABEO N/A
- 52 Week Low
- HSHP $4.29
- ABEO $3.93
- 52 Week High
- HSHP $9.76
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- HSHP 65.40
- ABEO 56.57
- Support Level
- HSHP $5.46
- ABEO $5.93
- Resistance Level
- HSHP $5.80
- ABEO $7.17
- Average True Range (ATR)
- HSHP 0.15
- ABEO 0.44
- MACD
- HSHP 0.02
- ABEO -0.01
- Stochastic Oscillator
- HSHP 78.79
- ABEO 50.00
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.